Ogilvy lands Endo pain, men's health work

Share this article:
Ogilvy lands Endo pain, men's health work
Ogilvy lands Endo pain, men's health work

Endo Health Solutions has named Ogilvy Public Relations (Ogilvy PR) as agency partner for its pharmaceutical business. Oglivy PR will offer communications support to the company's men's health and pain-management businesses.

PRWeek reported that the selection process took place over a few weeks and that it is an annual deal.

“Ogilvy's healthcare expertise combined with its global network and resource make this the right partnership as Endo broadens its reach in branded pharmaceuticals,” stated Blaine Davis, Endo SVP, corporate affairs, in a press release.

Endo Pharmaceuticals owns two testosterone injections, Delatestyrl and Fortesta, in addition to a number of pain management products, including Opana ER as well as Percocet, Percodan, Voltaren and Zydone.

Other brands include Fortesta Gel for Low-T, Supprelin LA for central precocious puberty, and bladder cancer treatment Valstar.

The FDA decided last spring to allow generic competition for Opana ER. Endo's 2013 third-quarter earnings presentation notes that commercial support for the brand is continuing, with a focus on driving organic growth through specialty promotion. Endo Health bought Canadian drugmaker Paladin Labs last November, netting the firm pain drug Zohydro, a non-combination hydrocodone product.

FDA approved Zohydro in late October, only one day after federal regulators announced that it would aim to tighten the control of hydrocodone products, like Vicodin, in an effort to reduce misuse and abuse of these products, by moving them from Schedule III to Schedule II.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...